SureTrader Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 6/30/2016 3:26:37 PM - Followers: 773 - Board type: Free - Posts Today: 103

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Securities Registration Statement (s-1) 06/27/2016 04:31:26 PM
ELTP News: Current Report Filing (8-k) 06/15/2016 04:39:41 PM
ELTP News: Annual Report (10-k) 06/15/2016 01:56:08 PM
ELTP News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 06/15/2016 12:52:59 PM
ELTP News: Elite Pharmaceuticals, Inc. (OTCMKTS: ELTP) Analyst Report; Action Date Under the Prescription Drug User Fee Act (“PDUFA” 06/13/2016 08:00:00 AM
PostSubject
#207474  Sticky Note These people cannot be help by the FDA lasers 06/24/16 06:10:52 PM
#207005  Sticky Note For new investors who want to learn more Dr_Thorfin 06/22/16 10:14:38 AM
#203141  Sticky Note How Pharma Copes with the Pain of Developing Moose45 06/06/16 08:11:20 AM
#200119  Sticky Note Dear WeeZuhl, WeeZuhl 05/15/16 10:56:35 AM
#189575  Sticky Note 4-REASONS-ELTP-is-in-the-Midst-of-the-Perfect-Storm:-A-GREAT-BUY-NOW: Couch 03/18/16 07:41:32 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#208457   The Accumulation Continues. NASDAQ2020 06/30/16 03:31:13 PM
#208456   Lots of information coming forward which demonstrates the Couch 06/30/16 03:26:37 PM
#208455   Perfect kennyt 335 06/30/16 03:20:42 PM
#208453   Wtf does that have to do with the Couch 06/30/16 03:17:57 PM
#208451   Sorry but Nasrat only mentioned what the Oxy Couch 06/30/16 03:12:10 PM
#208449   Pathetic! lasers 06/30/16 02:43:20 PM
#208447   Something else.. namtae 06/30/16 02:34:26 PM
#208446   Lots of information coming forward which demonstrates the namtae 06/30/16 02:31:05 PM
#208445   ER ADT's are on the market. Why aren't jour_trader 06/30/16 02:18:14 PM
#208444   Purdue attached to another object by an inclined NASDAQ2020 06/30/16 02:17:55 PM
#208443   If this was even remotely true don't you jour_trader 06/30/16 02:15:42 PM
#208442   The US Food and Drug Administration (FDA) NASDAQ2020 06/30/16 02:04:27 PM
#208441   Elite will own 100% of the abuse deterrent NASDAQ2020 06/30/16 01:59:53 PM
#208439   Even with FDA approval & labeling, this is Couch 06/30/16 01:05:00 PM
#208438   Califf understands Purdue's OxyContin is junk to begin Couch 06/30/16 12:58:12 PM
#208437   Yes sir YJ4LIFE! HOPE WE GET OUR FIREWORKS kennyt 335 06/30/16 12:54:10 PM
#208436   snup, no change in posture. I see it dr_lowenstein 06/30/16 12:51:39 PM
#208435   That's my prediction date. Let's do it FDA! YJ4LIFE 06/30/16 12:50:50 PM
#208434   PDUFA date isn't going to change. The labeling Couch 06/30/16 12:49:22 PM
#208429   Thanks snup. I'm sure Nas. Is on sharkey1 06/30/16 12:37:01 PM
#208428   Snup...exactly my thoughts. SCHH 06/30/16 12:27:30 PM
#208427   Even with FDA approval & labeling, this is namtae 06/30/16 12:26:42 PM
#208425   Dr.Lowenstein, ahh a change in posture? sequest oxy is snupoled 06/30/16 12:22:29 PM
#208424   90,000 bid at .3201, come get em. mrwrn2010 06/30/16 12:15:50 PM
#208423   Our doggedly, seasoned, beloved ceo is being lambasted snupoled 06/30/16 12:13:08 PM
#208422   Nasrat managed the risk as any solid CEO does. Couch 06/30/16 12:05:08 PM
#208420   Yes, those 5 FDA approved drugs really helped COO2002COO 06/30/16 12:01:12 PM
#208419   LOL LOL , of course!!! dr_lowenstein 06/30/16 12:00:07 PM
#208417   Wow! A great jump to close June Aqua 06/30/16 11:37:31 AM
#208416   I think he wanted to limit downside share joseytheoutlawwales 06/30/16 11:36:26 AM
#208415   Would be nice for an early fireworks display kennyt 335 06/30/16 11:36:15 AM
#208414   Adcom = adnauseum SCHH 06/30/16 11:36:00 AM
#208413   This is why Purdue is in deep trouble COO2002COO 06/30/16 11:34:23 AM
#208412   Like Califf says abuse deterrent formulas don't stop stockboy 06/30/16 11:32:41 AM
#208411   THE LONGEST!!! Remember when we had to toybaby 06/30/16 11:29:30 AM
#208410   I can relate Too sharkey1 06/30/16 11:26:33 AM
#208409   is Robert Califf, head of the FDA enough dr_lowenstein 06/30/16 11:24:57 AM
#208408   Fruition finally for $ELTP shareholders!!! lasers 06/30/16 11:21:31 AM
#208407   Yes that is correct! The FDA has had lasers 06/30/16 11:18:32 AM
#208406   I really don't know how I'm going to toybaby 06/30/16 11:13:57 AM
#208405   The FDA usually posts by 11 AM on lasers 06/30/16 11:05:16 AM
#208404   1+4+3= I don't count July 14 , so toybaby 06/30/16 11:03:18 AM
#208403   The FDA doesn't delay decisions unless they receive Chasing 06/30/16 10:56:41 AM
#208402   Yes these Fentanyl fake oxycodone drugs have been lasers 06/30/16 10:56:33 AM
#208401   Counterfeit OxyIR 30mg WeeZuhl 06/30/16 10:47:51 AM
#208400   The FDA has a solid reputation to maintain lasers 06/30/16 10:45:01 AM
#208399   PDUFA date isn't going to change. The labeling stockboy 06/30/16 10:43:31 AM
#208398   thanks for the response.. this makes sense... however, dest_golf 06/30/16 10:36:48 AM
#208397   Obviously the "ERR" is my opinion, as I Dr Speculator Ninja 06/30/16 10:29:11 AM
#208396   "Nasrat offered his more optimistic opinion of a COO2002COO 06/30/16 10:14:22 AM
PostSubject